Strategic Financing for Cutting-Edge Life Sciences Facility
D2 Capital Advisors recently organized a remarkable $26,000,000 in permanent financing for a state-of-the-art lab and R&D building within the Chestnut Run Innovation & Science Park. This project represents a significant step in enhancing the life sciences landscape.
The Vision Behind the Chestnut Run Project
Designed as an 80,000 square foot facility, the new building stands as a testament to modern science and research. Developed by MRA Group, well-known for expertise in life science campuses, this facility is set to support groundbreaking advancements in research and medicine.
Key Players in the Financing
Securing this financing was no small feat. The team from D2 Capital Advisors included distinguished professionals such as Jack Cortese, David Frankel, and John Lightcap. Their collective experience in life sciences financing was instrumental in navigating the complexities of the financing process.
Significance of the New Facility
This new life sciences building, which opened its doors recently, is fully occupied by Prelude Therapeutics, a clinical-stage precision oncology company renowned for developing innovative drug candidates. This partnership showcases the facility's role in advancing critical cancer research.
Transforming the Innovation Landscape
MRA Group has played a pivotal role in this transformation. Since acquiring the campus from DuPont, they have been on a mission to redevelop CRISP into a thriving ecosystem tailored for innovative companies. The campus, projected to exceed 1.3 million square feet, will foster scientific innovation and advanced production.
Feedback from Industry Leaders
Phil Butler, Executive Vice President & Partner of MRA Group, highlighted the importance of D2's expertise: "D2's life sciences financing experience and strong lender relationships were extremely valuable to us throughout the financing process. This financing was an important milestone in our redevelopment plan for CRISP, which affords us increased financial flexibility and demonstrates a broader confidence in the region by the capital markets."
Jack Cortese from D2 Capital Advisors emphasized the advantages CRISP offers: "It's easy to see why Prelude chose the CRISP Campus and MRA as developer to deliver this highly functional and aesthetically pleasing wet and dry lab building. However, there's still work to be done in showcasing Wilmington's advantages to potential lenders, underscoring the need for education about this burgeoning sub-market."
Location and Access
Positioned conveniently along the I-95 corridor, CRISP is within a short drive from Philadelphia, creating an inviting environment for businesses in the life sciences sector. This area is quickly becoming a hub for life sciences, bolstered by an abundance of skilled professionals, proximity to renowned research institutions, and a robust healthcare system.
About D2 Capital Advisors
D2 Capital Advisors serves as the transaction advisory arm of D2 Organization. Specializing in arranging and structuring real estate debt and equity, they support developers and investors across the nation, facilitating significant projects like this one.
Frequently Asked Questions
What is the purpose of the new lab building?
The facility aims to support research and development in the life sciences field, providing space for innovative companies to thrive.
Who developed the Chestnut Run facility?
MRA Group is the developer responsible for the construction of the new lab and R&D building.
Which company is occupying the new facility?
Prelude Therapeutics, a clinical-stage precision oncology company, has fully occupied the new building on a long-term lease.
What advantages does Wilmington offer for life sciences?
Wilmington boasts proximity to top research institutions, a skilled workforce, and is increasingly recognized as a favorable location for life sciences companies.
Who arranged the financing for the project?
D2 Capital Advisors, with key professionals Jack Cortese, David Frankel, and John Lightcap, arranged the $26 million financing.
